Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

v3.22.2.2
Accrued Expenses
 9 Months Ended
Jun. 30, 2022
Accrued Expenses  
Accrued Expenses

 

  3. Accrued Expenses

 

Accrued expenses consisted of the following:

 

    June 30,     September 30,  
    2022     2021  
Compensation and benefits   $ 911,954     $ 989,315  
Research and development     2,031,907       1,031,329  
Professional fees     245,731       286,688  
Other     14,546       3,078  
Accrued Expenses   $ 3,204,138     $ 2,310,410  

 

 

Sonnet BioTherapeutics Holdings, Inc.

Notes to Unaudited Interim Consolidated Financial Statements